Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers.
The identification of autoantibodies to tumor cell proteins by proteomics approaches has great potential impact on cancer biomarker discovery. The humoral immune response represents a form of biological amplification of signals that are otherwise weak due to very low concentrations of antigen, especially in the early stages of cancers. In addition, proteomics can detect immunoreactivity directed against protein post-translational modifications. Two-dimensional gel based Western blots, protein antigen microarrays, and multiplex ELISA reactions have been applied by our group to antigen based biomarker detection and validation. The latter two are based on liquid-phase separations that are suitable for automation. This work has resulted in the identification of numerous cancer biomarker candidates. Large clinical studies are currently planned to establish their value in early cancer diagnosis.
Imafuku
Yuji
Y
Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
Omenn
Gilbert S
GS
Hanash
Samir
S
D000912:Antibodies, Neoplasm / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000302:isolation & purification; D001323:Autoantibodies / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology; D015153:Blotting, Western / Q000379:methods; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D040081:Protein Array Analysis / Q000379:methods; D040901:Proteomics / Q000379:methods*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor